This page shows you your search results in order of date.
Order by Relevance | Date
Total 16 results found since Jan 2013.
Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500 000 patients with Type 2 diabetes mellitus
ConclusionCardiovascular disease-free life expectancy and effects of lifelong prevention in terms of CVD-free life-years gained can be estimated for people with T2DM using readily available clinical characteristics. Predictions of individual-level treatment effects facilitate translation of trial results to individual patients.
Source: European Heart Journal - January 9, 2019 Category: Cardiology Source Type: research
Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract
ConclusionLong-term statin treatment is remarkably safe with a low risk of clinically relevant adverse effects as defined above; statin-associated muscle symptoms were discussed in a previous Consensus Statement. Importantly, the established cardiovascular benefits of statin therapy far outweigh the risk of adverse effects.
Source: European Heart Journal - April 27, 2018 Category: Cardiology Source Type: research
Ten-year association of coronary artery calcium with atherosclerotic cardiovascular disease (ASCVD) events: the multi-ethnic study of atherosclerosis (MESA)
ConclusionsCoronary artery calcium is associated strongly and in a graded fashion with 10-year risk of incident ASCVD as it is for CHD, independent of standard risk factors, and similarly by age, gender, and ethnicity. While 10-year event rates in those with CAC = 0 were almost exclusively below 5%, those with CAC ≥ 100 were consistently above 7.5%, making these potentially valuable cutpoints for the consideration of preventive therapies. Coronary artery calcium strongly predicts risk with the same magnitude of effect in all races, age groups, an d both sexes, which makes it among the most useful markers for predicting ASCVD risk.
Source: European Heart Journal - April 23, 2018 Category: Cardiology Source Type: research
Cholesterol variability: a marker for increased risk or a risk factor?
This editorial refers to ‘Cholesterol variability and the risk of mortality, myocardial infarction, and stroke: a nationwide population-based study’†, by M.K. Kimet al., on page3560.
Source: European Heart Journal - November 13, 2017 Category: Cardiology Source Type: research
Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials
ConclusionReduction of MVE is proportional to the magnitude of LDL-C lowering across a broad spectrum of on-treatment levels in secondary prevention. Statin intensification and add-on treatment with PCSK9 inhibitors or ezetimibe are associated with significant reduction of cardiovascular morbidity in this very high-risk population.
Source: European Heart Journal - October 23, 2017 Category: Cardiology Source Type: research
Cholesterol variability and the risk of mortality, myocardial infarction, and stroke: a nationwide population-based study
ConclusionHigh variability in lipid levels is associated with adverse health-related outcomes. These findings suggest that lipid variability is an important risk factor in the general population.
Source: European Heart Journal - October 21, 2017 Category: Cardiology Source Type: research
Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995–2014
ConclusionGradual implementation of new and established evidence-based treatments in STEMI patients during the last 20 years has been associated with prolonged survival and lower risk of recurrent ischaemic events, although a plateauing is seen since around 2008.
Source: European Heart Journal - August 29, 2017 Category: Cardiology Source Type: research
Differential effects of PCSK9 variants on risk of coronary disease and ischaemic stroke
ConclusionPCSK9 genetic variants that confer life-long lower PCSK9 and LDL-C levels appear to have significantly weaker, if any, associations with risk of IS than with risk of CHD. By contrast, similar proportional reductions in risks of IS and CHD have been observed in randomized trials of therapeutic PCSK9-inhibition. These findings have implications for our understanding of when Mendelian randomization can be relied upon to predict the effects of therapeutic interventions.
Source: European Heart Journal - July 17, 2017 Category: Cardiology Source Type: research
Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial
ConclusionAlthough intensive lowering with standard pitavastatin plus ezetimibe showed no more cardiovascular benefit than standard pitavastatin monotherapy in ACS patients with dyslipidaemia, statin plus ezetimibe may be more effective than statin monotherapy in patients with higher cholesterol absorption; further confirmation is needed.Trial NoUMIN000002742, registered as an International Standard Randomized Controlled Trial.
Source: European Heart Journal - April 18, 2017 Category: Cardiology Source Type: research
The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial
Conclusion The clinical benefit of adding ezetimibe to statin appears to be enhanced in patients with prior CABG, supporting the use of intensive lipid lowering therapy in these high-risk patients following ACS.
Source: European Heart Journal - January 13, 2017 Category: Cardiology Authors: Eisen, A., Cannon, C. P., Blazing, M. A., Bohula, E. A., Park, J.-G., Murphy, S. A., White, J. A., Giugliano, R. P., Braunwald, E., on behalf of the IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial) Investigators Tags: Acute coronary syndromes Source Type: research
Heterogeneous impact of classic atherosclerotic risk factors on different arterial territories: the EPIC-Norfolk prospective population study
Conclusion The heterogeneity in the risk factor–CVD associations supports the concept of pathophysiological differences between atherosclerotic CVD manifestations and could have implications for CVD prevention.
Source: European Heart Journal - March 14, 2016 Category: Cardiology Authors: Stoekenbroek, R. M., Boekholdt, S. M., Luben, R., Hovingh, G. K., Zwinderman, A. H., Wareham, N. J., Khaw, K.-T., Peters, R. J. G. Tags: Prevention and epidemiology Source Type: research
Association between pre-operative statin use and major cardiovascular complications among patients undergoing non-cardiac surgery: the VISION study
Conclusion Among patients undergoing non-cardiac surgery, pre-operative statin therapy was independently associated with a lower risk of cardiovascular outcomes at 30 days. These results require confirmation in a large randomized trial. Clinical trial registration Clinical Trials.gov NCT00512109
Source: European Heart Journal - January 7, 2016 Category: Cardiology Authors: Berwanger, O., Le Manach, Y., Suzumura, E. A., Biccard, B., Srinathan, S. K., Szczeklik, W., Santo, J. A. E., Santucci, E., Cavalcanti, A. B., Archbold, R. A., Devereaux, P. J., for the VISION Investigators Tags: ESC Clinical Registry Source Type: research
Prognosis and treatment of atrial fibrillation patients by European cardiologists: One Year Follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry)
Conclusion In this 1-year follow-up analysis of the EORP-AF pilot general registry, we provide data on the first contemporary registry focused on management practices among European cardiologists, conducted since the publication of the new ESC guidelines. Overall OAC use remains high, although persistence with therapy may be problematic. Nonetheless, continued OAC use was more common than in prior reports. Despite the high prescription of OAC, 1-year mortality and morbidity remain high in AF patients, particularly from heart failure and hospitalizations.
Source: European Heart Journal - December 14, 2014 Category: Cardiology Authors: Lip, G. Y. H., Laroche, C., Ioachim, P. M., Rasmussen, L. H., Vitali-Serdoz, L., Petrescu, L., Darabantiu, D., Crijns, H. J. G. M., Kirchhof, P., Vardas, P., Tavazzi, L., Maggioni, A. P., Boriani, G. Tags: Fast Track ESC Clinical Trial and Registry Update Source Type: research
Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry
Conclusion Among patients with PAD in the REACH registry, statin use was associated with an ~18% lower rate of adverse limb outcomes, including worsening symptoms, peripheral revascularization, and ischaemic amputations. These findings suggest that statin therapy not only reduces the risk of adverse cardiovascular events, but also favourably affects limb prognosis in patients with PAD.
Source: European Heart Journal - November 1, 2014 Category: Cardiology Authors: Kumbhani, D. J., Steg, P. G., Cannon, C. P., Eagle, K. A., Smith, S. C., Goto, S., Ohman, E. M., Elbez, Y., Sritara, P., Baumgartner, I., Banerjee, S., Creager, M. A., Bhatt, D. L., on Behalf of the REACH Registry Investigators Tags: Vascular medicine Source Type: research
Lipid lowering in patients with treatment-resistant hypertension: an analysis from the Treating to New Targets (TNT) trial
Conclusion In subjects with TRH, intensive lipid lowering with atorvastatin 80 mg is associated with a significant reduction in cardiovascular events.
Source: European Heart Journal - July 15, 2014 Category: Cardiology Authors: Bangalore, S., Fayyad, R., Laskey, R., DeMicco, D., Deedwania, P., Kostis, J. B., Messerli, F. H., Treating to New Targets Steering Committee and Investigators Tags: Heart failure/cardiomyopathy Source Type: research
Renin-angiotensin system antagonists and clinical outcomes in stable coronary artery disease without heart failure
Conclusions Use of ACEI/ARB was not associated with better outcomes in stable CAD outpatients without HF. The benefit of ACEI/ARB seen in randomized clinical trials was not replicated in this large contemporary cohort, which questions their value in this specific subset.
Source: European Heart Journal - July 7, 2014 Category: Cardiology Authors: Sorbets, E., Labreuche, J., Simon, T., Delorme, L., Danchin, N., Amarenco, P., Goto, S., Meune, C., Eagle, K. A., Bhatt, D. L., Steg, P. G. Tags: Coronary artery disease Source Type: research